SLN360
Silence Therapeutics
[]
$sln silence therapeutics presents new analysis from sln360 phase 1 single dose study in high lipoprotein(a) at the american heart association (aha) 2022 annual meeting 1/2
¬ Retweeting Bloomberg's Feed all in one place.

¬ Market & Stock Updates

¬ I'm Barry Bloomberg putting out the fastest updates!

¬ Making your life easier.